Search results for "Idiot"
showing 10 items of 44 documents
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
2010
An important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including EGFR activation markers and EGFR ligands activation markers. With regard to the "negative predictive factors" responsible for primary or intrinsic resistance to anti-EGFR antibodies a lot of data are now available. Among these, KRAS mutations have emerged as a major predictor of resistance to panitumumab or cetuximab in the clinical setting and several studies of patients receiving first and subsequent lines of treatment have sho…
Fjodora Dostojevska romāna "Idiots" iepazīšana literatūras stundās 11. klasē
2016
Diplomdarba “Fjodora Dostojevska romāna “Idiots” iepazīšana literatūras stundās 11. klasē” mērķis ir izstrādāt un aprobēt mācību materiālus, kas rosinātu skolēnus iepazīt Fjodora Dostojevska romānu “Idiots” kopveselumā. Pētījuma problēma: Kā veidot mācību saturu, kas sekmē skolēnu interesi iepazīt daiļdarbu kopveselumā? Diplomdarba struktūru veido piecas nodaļas; 1.Literatūra kā mācību priekšmets; 2.Fjodora Dostojevska dzīves gājums un devums pasaules literatūrā; 3.Skolotāja sagatavošanās darbam klasē; 4.Skolotājas un skolēnu sadarbība literatūras stundās; 5.Skolotājas un skolēnu sadarbības rezultātu analīze un izvērtējums. Diplomdarba pirmajā nodaļā ir aprakstītas nozīmīgākās pedagoģijas u…
Anti-Idiotypic Antibodies Against the Kinin Receptor
1992
Three sets of monoclonal antibodies against bradykinin (MBK1, MBK2, and MBK3) were generated by somatic cell fusion, characterized by their peptide specificity, and compared with the known ligand specificity of the kinin receptor subtypes. By these criteria, the paratope of MBK3 resembled the B 2 receptor binding site, whereas MBK1 shared principal binding characteristics with the B 1 receptor. Anti-idiotypic antibodies against MBK1, MBK2, and MBK3 were raised in rabbit and sheep
Lecciones de psicología: notas sobre la lectura nietzscheana de 'Humillados y ofendidos' de Dostoievski
2012
espanolE: Este texto, primera parte de un extenso estudio sobre la lectura nietzscheana de Humillados y ofendidos de F. Dostoievski, arranca con una reflexion sobre la actualidad del analisis de las relaciones entre ambos escritores como un reto que sigue abierto en la Nietzsche-Forschung. Desde los documentos que testimonian dicha lectura y sus efectos («mit dem grossten Respekt vor dem Kunstler Dostoiewsky»), se evidencia que hay que clarificar la concepcion del artista que aqui se manifiesta. las cartas de Nietzsche demuestran por otra parte que el filosofo valoro al escritor ruso sobre todo en cuanto psicologo, segundo tema a explicitar. los textos de E. M. de la Vogue sobre Dostoievski…
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
2010
Omalizumab is approved for the treatment of severe allergic asthma.To compare the efficacy of omalizumab therapy in patients 50 years or older with patients younger than 50 years.Between November 2005 and November 2007 a total of 174 asthma patients 50 years or older (40.7% male, 51.1% taking oral corticosteroids, and mean [SD] serum IgE level of 315 [353] U/L) and 297 asthma patients younger than 50 years (40.0% male, 50.5% taking oral corticosteroids, and mean [SD] serum IgE level of 363 [431] U/L) who met the European Union criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab for 4 months as part of 2 postmarketing surveillance trials.Compared with the pre…
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.
2002
The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-t…
Against all odds: anti-IgE for intrinsic asthma?
2013
For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.
The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
2009
SummarySevere persistent asthma causes a substantial morbidity and mortality burden and is frequently inadequately controlled despite intensive guideline-based therapy. Targeting allergic inflammatory processes that underlie the pathogenesis of severe persistent asthma improves asthma control in a significant proportion of patients. Omalizumab, a humanized monoclonal anti-immunoglobulin E (IgE) antibody, has been developed to target IgE, which is central to triggering and maintaining allergic airway inflammation. In a comprehensive program of clinical trials, omalizumab has been shown to reduce asthma exacerbation and emergency visit rates, and to improve quality of life in patients with se…
Eligibility for treatment with omalizumab in Italy and Germany.
2013
Summary Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Europe, patients must fulfil a number of additional criteria to become eligible for omalizumab therapy, creating a challenge for epidemiology studies to quantify the potential patient pool. Thus, and in the absence of robust data, the number of omalizumab-eligible patients has remained unclear. To assess eligible patient numbers, a chart-audit design approach was employed to measure epidemiology variables based on patient-level data. 770 patient charts were reviewed in designated towns in Germany and Italy, in collaboration with >200 primary care physicians (PCPs) and respiratory specialists (R…
Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies.
2001
The induction of anti-DNA autoantibodies in systemic lupus erythematosus (SLE) patients is problematic because mammalian DNA is poorly immunogenic at best. Here we demonstrate a chain of connected antibodies in SLE patient sera that could account for the induction of anti-DNA antibody, and possibly for some of the pathogenic features of SLE. We now report that SLE patients, in addition to anti-DNA, produce antibodies to the carboxy-terminal domain of the tumour suppressor molecule p53; this p53 domain recognizes damaged DNA. Hence, these anti-p53 antibodies could mimic damaged DNA immunologically. Indeed, SLE sera do contain anti-idiotypic antibodies to a prototypic anti-p53 antibody. Moreo…